Description: Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2016

Summary


The report provides comprehensive information on the therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction
- The report reviews pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Adenocarcinoma Of The Gastroesophageal Junction therapeutics and enlists all their major and minor projects
- The report assesses Adenocarcinoma Of The Gastroesophageal Junction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devises corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
List of Tables
List of Figures
Introduction
Report Coverage
Adenocarcinoma Of The Gastroesophageal Junction Overview
Therapeutics Development
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Investigation by Universities/Institutes
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies
Adenocarcinoma Of The Gastroesophageal Junction - Products under Investigation by Universities/Institutes
Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development
AB Science SA
AbbVie Inc.
Advenchen Laboratories, LLC
Amgen Inc.
ArQule, Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment

Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(tipiracil hydrochloride + trifluridine) - Drug Profile
AL-3818 - Drug Profile
alisertib - Drug Profile
alpelisib - Drug Profile
AMG-337 - Drug Profile
atezolizumab - Drug Profile
avelumab - Drug Profile
AZD-4547 - Drug Profile
AZD-6738 - Drug Profile
BI-853520 - Drug Profile
cabazitaxel - Drug Profile
catumaxomab - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
ceritinib - Drug Profile
CRLX-101 - Drug Profile
DS-8201 - Drug Profile
durvalumab - Drug Profile
durvalumab + tremelimumab - Drug Profile
emibetuzumab - Drug Profile
erdafitinib - Drug Profile
GS-5745 - Drug Profile
Her-VAXX - Drug Profile
ibrutinib - Drug Profile
IMAB-362 - Drug Profile
indusatumab vedotin - Drug Profile
ipatasertib - Drug Profile
ipilimumab - Drug Profile
LAG-525 - Drug Profile
LY-3127804 - Drug Profile
masitinib - Drug Profile
MBP-426 - Drug Profile
merestinib - Drug Profile
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H1 2016
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science SA, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AbbVie Inc., H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Advenchen Laboratories, LLC, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca Plc, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech, Inc., H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Hutchison MediPharma Limited, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Imugene Limited, H1 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Johnson & Johnson, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3753824/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3753824/">http://www.researchandmarkets.com/reports/3753824/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD2LPRS</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Formats</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 6000</td>
</tr>
<tr>
<td>Enterprise wide:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐  Mrs ☐  Dr ☐  Miss ☐  Ms ☐  Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World